- Home
- PSNYW vs RIGL Comparison
PSNYW vs RIGL Comparison
Compare PSNYW & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNYW
- RIGL
- Stock Information
- Founded
- PSNYW 2017
- RIGL 1996
- Country
- PSNYW Sweden
- RIGL United States
- Employees
- PSNYW 2547
- RIGL N/A
- Industry
- PSNYW Auto Manufacturing
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- PSNYW Consumer Discretionary
- RIGL Health Care
- Exchange
- PSNYW Nasdaq
- RIGL Nasdaq
- Market Cap
- PSNYW 625.2M
- RIGL 335.5M
- IPO Year
- PSNYW N/A
- RIGL 2000
- Fundamental
- Price
- PSNYW $0.30
- RIGL $38.85
- Analyst Decision
- PSNYW
- RIGL Buy
- Analyst Count
- PSNYW 0
- RIGL 5
- Target Price
- PSNYW N/A
- RIGL $38.20
- AVG Volume (30 Days)
- PSNYW 43.4K
- RIGL 995.6K
- Earning Date
- PSNYW 03-06-2025
- RIGL 08-05-2025
- Dividend Yield
- PSNYW N/A
- RIGL N/A
- EPS Growth
- PSNYW N/A
- RIGL N/A
- EPS
- PSNYW N/A
- RIGL 5.43
- Revenue
- PSNYW $2,034,261,000.00
- RIGL $267,921,000.00
- Revenue This Year
- PSNYW N/A
- RIGL $59.93
- Revenue Next Year
- PSNYW $79.49
- RIGL N/A
- P/E Ratio
- PSNYW N/A
- RIGL $7.15
- Revenue Growth
- PSNYW N/A
- RIGL 105.62
- 52 Week Low
- PSNYW $0.09
- RIGL $12.66
- 52 Week High
- PSNYW $0.61
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- PSNYW 56.04
- RIGL 68.57
- Support Level
- PSNYW $0.16
- RIGL $39.00
- Resistance Level
- PSNYW $0.80
- RIGL $42.08
- Average True Range (ATR)
- PSNYW 0.06
- RIGL 2.32
- MACD
- PSNYW 0.02
- RIGL -0.37
- Stochastic Oscillator
- PSNYW 15.62
- RIGL 53.26
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.